JOP20210166A1 - علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r - Google Patents
علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-rInfo
- Publication number
- JOP20210166A1 JOP20210166A1 JOP/2021/0166A JOP20210166A JOP20210166A1 JO P20210166 A1 JOP20210166 A1 JO P20210166A1 JO P20210166 A JOP20210166 A JO P20210166A JO P20210166 A1 JOP20210166 A1 JO P20210166A1
- Authority
- JO
- Jordan
- Prior art keywords
- cgrp
- antibodies
- treatment
- overuse headache
- drug overuse
- Prior art date
Links
- 206010019233 Headaches Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 231100000869 headache Toxicity 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789828P | 2019-01-08 | 2019-01-08 | |
| US201962840967P | 2019-04-30 | 2019-04-30 | |
| US201962841585P | 2019-05-01 | 2019-05-01 | |
| US201962872983P | 2019-07-11 | 2019-07-11 | |
| PCT/US2020/012790 WO2020146535A1 (en) | 2019-01-08 | 2020-01-08 | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210166A1 true JOP20210166A1 (ar) | 2023-01-30 |
Family
ID=71404208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0166A JOP20210166A1 (ar) | 2019-01-08 | 2020-01-08 | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20200216525A1 (enExample) |
| EP (1) | EP3908607A4 (enExample) |
| JP (2) | JP2022516957A (enExample) |
| KR (1) | KR20210114002A (enExample) |
| CN (2) | CN113272324A (enExample) |
| AU (1) | AU2020207299A1 (enExample) |
| BR (1) | BR112020018044A2 (enExample) |
| CA (1) | CA3123292A1 (enExample) |
| CL (1) | CL2021001813A1 (enExample) |
| CO (1) | CO2021008665A2 (enExample) |
| DO (1) | DOP2021000145A (enExample) |
| EC (1) | ECSP21052193A (enExample) |
| GE (2) | GEAP202515689A (enExample) |
| IL (1) | IL284677A (enExample) |
| JO (1) | JOP20210166A1 (enExample) |
| MA (1) | MA54709A (enExample) |
| MX (1) | MX2021008268A (enExample) |
| NI (1) | NI202100063A (enExample) |
| PE (1) | PE20211708A1 (enExample) |
| PH (1) | PH12021551494A1 (enExample) |
| SG (1) | SG11202106878XA (enExample) |
| TW (1) | TW202030205A (enExample) |
| UA (1) | UA129265C2 (enExample) |
| WO (1) | WO2020146535A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2709662T3 (da) | 2011-05-20 | 2019-11-04 | Alderbio Holdings Llc | Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré |
| SMT201900293T1 (it) | 2011-05-20 | 2019-07-11 | Alderbio Holdings Llc | Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo |
| EP3508501B1 (en) | 2011-05-20 | 2024-11-06 | H. Lundbeck A/S | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| EP3908606A4 (en) | 2019-01-08 | 2022-11-23 | H. Lundbeck A/S | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES |
| BR102020007149A8 (pt) | 2020-04-06 | 2023-09-26 | H Lundbeck As | Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca |
| KR20240049275A (ko) * | 2021-08-27 | 2024-04-16 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용한 군발성 두통의 치료 |
| EP4570913A1 (en) * | 2022-08-11 | 2025-06-18 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cgrp antibody and use |
| CN118476508A (zh) * | 2024-06-27 | 2024-08-13 | 中国人民解放军总医院第一医学中心 | 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070065463A1 (en) * | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| SMT201900293T1 (it) * | 2011-05-20 | 2019-07-11 | Alderbio Holdings Llc | Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo |
| EP3508501B1 (en) * | 2011-05-20 | 2024-11-06 | H. Lundbeck A/S | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| CN103585449B (zh) * | 2013-10-23 | 2016-06-22 | 高丽丽 | 用于治疗偏头痛的中药组合物 |
| WO2016168757A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| CA3036632A1 (en) * | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| EP3908606A4 (en) * | 2019-01-08 | 2022-11-23 | H. Lundbeck A/S | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES |
-
2020
- 2020-01-08 PE PE2021001141A patent/PE20211708A1/es unknown
- 2020-01-08 CN CN202080007409.XA patent/CN113272324A/zh active Pending
- 2020-01-08 JO JOP/2021/0166A patent/JOP20210166A1/ar unknown
- 2020-01-08 WO PCT/US2020/012790 patent/WO2020146535A1/en not_active Ceased
- 2020-01-08 AU AU2020207299A patent/AU2020207299A1/en active Pending
- 2020-01-08 EP EP20738512.1A patent/EP3908607A4/en active Pending
- 2020-01-08 GE GEAP202515689A patent/GEAP202515689A/en unknown
- 2020-01-08 PH PH1/2021/551494A patent/PH12021551494A1/en unknown
- 2020-01-08 MX MX2021008268A patent/MX2021008268A/es unknown
- 2020-01-08 BR BR112020018044-0A patent/BR112020018044A2/pt unknown
- 2020-01-08 TW TW109100630A patent/TW202030205A/zh unknown
- 2020-01-08 GE GEAP202015689A patent/GEP20257804B/en unknown
- 2020-01-08 UA UAA202104194A patent/UA129265C2/uk unknown
- 2020-01-08 MA MA054709A patent/MA54709A/fr unknown
- 2020-01-08 JP JP2021539682A patent/JP2022516957A/ja not_active Withdrawn
- 2020-01-08 US US16/736,937 patent/US20200216525A1/en not_active Abandoned
- 2020-01-08 KR KR1020217023581A patent/KR20210114002A/ko active Pending
- 2020-01-08 SG SG11202106878XA patent/SG11202106878XA/en unknown
- 2020-01-08 CA CA3123292A patent/CA3123292A1/en active Pending
- 2020-01-08 CN CN202411285298.5A patent/CN119303074A/zh active Pending
-
2021
- 2021-06-30 CO CONC2021/0008665A patent/CO2021008665A2/es unknown
- 2021-07-07 NI NI202100063A patent/NI202100063A/es unknown
- 2021-07-07 CL CL2021001813A patent/CL2021001813A1/es unknown
- 2021-07-07 DO DO2021000145A patent/DOP2021000145A/es unknown
- 2021-07-07 IL IL284677A patent/IL284677A/en unknown
- 2021-07-14 EC ECSENADI202152193A patent/ECSP21052193A/es unknown
-
2023
- 2023-11-16 US US18/511,241 patent/US20240343784A1/en active Pending
-
2024
- 2024-11-08 JP JP2024195562A patent/JP2025032102A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3123292A1 (en) | 2020-07-16 |
| CL2021001813A1 (es) | 2021-12-24 |
| ECSP21052193A (es) | 2021-08-31 |
| US20200216525A1 (en) | 2020-07-09 |
| TW202030205A (zh) | 2020-08-16 |
| WO2020146535A1 (en) | 2020-07-16 |
| CO2021008665A2 (es) | 2021-07-19 |
| CN119303074A (zh) | 2025-01-14 |
| PH12021551494A1 (en) | 2023-05-08 |
| MA54709A (fr) | 2022-04-13 |
| GEP20257804B (en) | 2025-10-10 |
| JP2025032102A (ja) | 2025-03-11 |
| UA129265C2 (uk) | 2025-03-05 |
| US20240343784A1 (en) | 2024-10-17 |
| IL284677A (en) | 2021-08-31 |
| GEAP202515689A (en) | 2025-04-25 |
| SG11202106878XA (en) | 2021-07-29 |
| AU2020207299A1 (en) | 2021-08-26 |
| PE20211708A1 (es) | 2021-09-01 |
| CN113272324A (zh) | 2021-08-17 |
| EP3908607A1 (en) | 2021-11-17 |
| BR112020018044A2 (pt) | 2021-08-10 |
| NI202100063A (es) | 2021-12-01 |
| DOP2021000145A (es) | 2021-10-31 |
| KR20210114002A (ko) | 2021-09-17 |
| MX2021008268A (es) | 2021-08-05 |
| EP3908607A4 (en) | 2022-10-05 |
| JP2022516957A (ja) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| EA202092668A1 (ru) | Антитела к ил-11 | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| MX2018012492A (es) | Métodos para monitorear y tratar el cáncer. | |
| CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
| BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| CY1124238T1 (el) | Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης | |
| EA201891925A1 (ru) | Антитела к cd40 с усиленной агонистической активностью | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| EA201892525A1 (ru) | Конструкции днк-антител для применения против pseudomonas aeruginosa | |
| EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| EA201992522A1 (ru) | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| JOP20210247A1 (ar) | علاج الصداع باستخدام أجسام مضادة لـ cgrp | |
| EA201990559A1 (ru) | Комбинированная терапия |